This article is more than 5 years old. Information may no longer be current.

RXi initiates phase 1/2 clinical trial of RXI-109 for retinal scarring

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

RXi Pharmaceuticals has initiated RXI-109-1501, a phase 1/2 clinical trial evaluating the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, according to a press release.

RXI-109-1501 includes patients diagnosed with wet age-related macular degeneration who will receive a total of four doses of RXI-109 in one eye only at 1-month intervals. The dosing period will last 3 months and will be followed by a 4-month observation period.

Investigators will evaluate the safety, tolerability and clinical activity of RXI-109, a self-delivering RNAi compound developed to target connective tissue growth factor, by using numerous assessments to monitor ocular health and visual acuity of patients, the release said.

“Currently, there is no effective way to prevent the formation or progression of retinal scars that may occur as a consequence of several devastating ocular diseases,” Pamela Pavco, PhD, chief development officer of RXi Pharmaceuticals, said in the release. “RXI-109 has the potential to fill this unmet medical need by reducing this continuing damage to the retina and, in doing so, helping to preserve vision in these individuals for a longer period of time.”